Operationalizing Bispecific Therapy and the Impact of CAR T Advancements on Sequencing

Key Takeaways

• Strategic sequencing of bispecific antibodies and CAR T-cell therapy is crucial for optimizing outcomes in RRMM treatment.
• Operational challenges include coordinating multidisciplinary teams, managing toxicities, and ensuring timely access to therapies.
• Streamlined communication and robust monitoring protocols are essential for addressing therapy-related challenges.
• Enhancing logistical frameworks facilitates efficient delivery of advanced therapies, improving patient experience and therapeutic efficacy.